-- Days : -- HRS : -- MIN : -- SEC
Register Now →
News|Articles|May 1, 2005

First-time generic approvals

Anti-sense compound (LR3001, Genta) for the treatment of chronic myelocytic leukemia

Dantrolene capsules 25, 50, and 100 mg (equiv to Dantrium capsules)
IMPAX

Griseofulvin oral suspension 125 mg/5 mL (equiv to Grifuvin V)
STIEFEL

Octreotide injection (preservative free) 0.05, 0.1, and 0.5 mg/mL (equiv to Sandostatin)
BEDFORD


Related to this article

2.3 Million Reasons to Rethink Member Communications Before January 1
CMS projects roughly 2.3 million people will lose Medicaid coverage in 2027 under the new community engagement requirements, also referred to as work requirements: four in ten to paperwork, not noncompliance. Arkansas showed how that happens; here is what plans can learn before the clock starts.